Last updated 8 days ago
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
240 patients around the world
Available in United States, Brazil
EyePoint Pharmaceuticals, Inc.
4Research sites
240Patients around the world
This study is for people with
Diabetic retinopathy
Diabetic macular edema
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Previously treated or treatment naïve patients with a documented diagnosis of macular edema associated with diabetic retinopathy (DR) in the study eye, with onset of disease that began at any time prior to the Screening Visit.Best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 35 letters (20/200 Snellen equivalent) to 78 letters (20/32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1).For previously treated participants: at least 1 injection of anti-VEGF in the past 12 months, the most recent anti-VEGF treatment for DME must not have been administered less than 12 weeks prior to the Screening Visit.
- BCVA using ETDRS charts <30 letters (20/250 Snellen equivalent) in the fellow eye.
Sites
Vision Institute - IPEPO (IPEPO - Instituto da Visão - Vila Clementino)
Recruiting
Retina Prime
Recruiting
Retina Clinic
Recruiting
Centro Brasileiro de Pesquisa Clínica Blumenau
Recruiting
StudyDME
SponsorEyePoint Pharmaceuticals, Inc.
Study typeInterventional
Conditions
Diabetic macular edema
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07449923
